Our Story

Entasis Therapeutics was established in 2015 as a spin-out from and with initial funding from AstraZeneca, and all rights to AstraZeneca’s industry-leading discovery and early development small-molecule anti-infectives portfolio. Since receiving our funding from AstraZeneca, we have raised $81.9 million in gross proceeds from equity financings from several U.S. and European healthcare specialist investment firms, including Clarus Lifesciences, Novo Holdings A/S, Frazier Life Sciences, Pivotal bioVenture Partners, TPG Biotechnology Partners, Sofinnova, and Eventide Funds, to advance our pipeline of breakthrough anti-infective products.